FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 295 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo... June 10, 2025 Cancer “Decoys” Planted Underneath The Skin Lure In Cancer Cells And... November 4, 2019 Magnetic Fish-Shaped Microbots Deliver Chemotherapy to Exactly Where It’s Needed December 9, 2021 Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in... October 19, 2023 Load more HOT NEWS Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with... NHS lung cancer patients in England to get early access to... Mom Spots Strange Glow In Daughter’s Eye While Looking At Photo,... FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes
